The Financial Times reported that a Chinese trial for Gilead Sciences's (GILD) antiviral drug remdesivir against Covid-19 ended without meaningful conclusions on its efficacy. That was enough to reverse the gains in the Standard & Poor's 500 on the day. The index had been up 1.28% as of 12:30 p.m. New York time. It ended […]
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.
